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OBJECTIVES: Data on the factors that contribute to the antibody response to hepatitis B virus vaccination in
peritoneal dialysis patients are scarce. The current study was conducted on a group of peritoneal dialysis patients to
learn how the response to hepatitis B virus vaccination varies according to the patient’s clearance of urea
normalized to total body water (Kt/V).
METHODS: A convenience sample of 33 peritoneal dialysis patients (13 women and 20 men, with a mean age of
49¡12 years) was administered double doses (20 mg IM in each deltoid muscle) of recombinant hepatitis B vaccine
at 0, 1, 2, and 6 months. Response to immunization was measured at one to three months after the final dose of
vaccine. The subjects were divided into groups according to the level of antibodies to hepatitis B surface antigen
(anti-HBs), including non-responders (,10 IU/L), weak responders (10-100 IU/L), and good responders (.100 IU/L).
RESULTS: Among non-responders, weak responders, and good responders, significant differences were found in
age (54¡12 vs. 56¡9 vs. 45¡12 years, respectively; p=0.049) and recombinant human erythropoietin use (20 vs. 29
vs. 76%, respectively; p=0.016). No significant differences in weekly total Kt/V (p=0.704), weekly peritoneal Kt/V
(p=0.064) and residual glomerular filtration rate (p=0.355) were found across the three groups.
CONCLUSIONS: Delivered clearance measured by weekly peritoneal Kt/V and total clearance measured by weekly
total Kt/V did not predict the response to hepatitis B virus vaccination in patients on peritoneal dialysis.
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INTRODUCTION
Control of a hepatitis B virus (HBV) infection has been a
continuous challenge in the management of patients with
end-stage renal disease (ESRD). Patients undergoing hemo-
dialysis (HD) are particularly at risk for HBV infection.1 In
contrast to HD patients, patients on peritoneal dialysis (PD)
appear to be at low risk for HBV infection. Nevertheless, all
susceptible ESRD patients, including those on PD, are
encouraged to be vaccinated because it is likely that they
will eventually need HD when PD becomes unfeasible,
either temporarily or permanently.2 Furthermore, the
peritoneal dialysate of patients positive for the hepatitis B
surface antigen (HBsAg) contains sufficient infectious
particles to cause hepatitis outbreaks in dialysis units.3,4
Uremic patients elicit weak response to vaccination with
recombinant HBV vaccine.5 To improve the immunogeni-
city of HBV vaccination for dialysis-dependent patients, the
vaccine should be administered at a dose of 40 mg, in
contrast to the 20 mg dose for healthy adults, through the
intramuscular route.6 Moreover, instead of a three-dose
schedule (i.e., 0, 1, and 6 months), a four-dose schedule (i.e.,
0, 1, 2, and 6 months) is recommended.6 Blood antibody
levels of hepatitis B antigen (anti-HBs) $10 IU/L are
considered protective in healthy individuals; however,
some authors believe that higher levels (.100 IU/L) are
desirable in patients on chronic HD.7,8
Factors associated with a favorable response to HBV
vaccination in HD patients include young age, good nutri-
tional status, and effective dialysis.1,5,9 Dialysis adequacy is
defined as the weekly clearance of urea normalized to total
body water (Kt/V). To date, only four studies have described
the effects of dialysis adequacy on HBV vaccination response
in PD patients. The results of these studies, however, have
been inconclusive.10-13 We conducted this study on a group of
PD patients undergoing PD to demonstrate how the response
to HBV vaccination varies with weekly Kt/V.
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METHODS AND MATERIALS
The Faculty of Medicine Ethics Committee of Kocaeli
University School of Medicine approved this prospective
observational study protocol, and all of the patients provided
written informed consent before entry into the study. Both
incident and prevalent PD patients over the age of 18 years
with ESRD at our university hospital clinic were screened for
HBV markers. Patients with negative HBsAg, negative
antibodies to hepatitis B surface antigen (anti-HBs), and
negative antibodies to hepatitis B core antigen (anti-HBc)
were included in the study. Patients using immunosuppres-
sive agents or patients with a history of malignancy, human
immunodeficiency virus (HIV) infection, alcoholic liver dis-
ease, HBV vaccination, abnormal liver function results during
the six months prior to recruitment, or positivity for HBsAg,
anti-HBs, or anti-HBc at any time in the past were excluded.
Peritoneal dialysis patients were on a standard continuous
ambulatory peritoneal dialysis (CAPD) program, with four or
five administrations daily of 2000 mL each.
Between January 2009 and May 2010, all participants were
administered double doses (20 mg IM in each deltoid
muscle) of recombinant hepatitis B vaccine (Euvax B, LG
Life Sciences, Jeonbuk-do, Korea) at 0, 1, 2, and 6 months.
The antibody response was determined by measuring the
HBsAg antibody 1 to 3 months after the last dose of vaccine.
Anti-HBs titers were measured using a commercial enzyme
immunoassay kit (Cobas, Roche Diagnostics GmBH,
Mannheim, Germany).
Demographic and clinical data, including age, gender,
body mass index (weight/height2), primary renal disease,
recombinant human erythropoietin (rHuEpo) use, and time
on dialysis, were recorded at study entry. Hemoglobin,
urea, creatinine, albumin, and high sensitivity C-reactive
protein (hs-CRP) were measured in venous blood samples.
Patients who had anti-HBs antibody levels ,10 IU/L
after the fourth dose of vaccine were considered non-
responders. Responders were divided into weak responders
(an anti-HBs level after the last vaccine dose of 10-100 IU/L)
and good responders (an anti-HBs level after the last
vaccine dose .100 IU/L).5
All participants underwent assessments of peritoneal
membrane function and residual renal function during the
vaccination process. Peritoneal membrane function was
evaluated by the standard peritoneal equilibrium test (PET)
using a 2.5% glucose PD solution.14 Adequacy was
calculated as weekly total Kt/V (weekly clearance of urea
normalized to total body water). Peritoneal Kt/V was
calculated by performing a 24-hour collection of dialysate
effluent and measuring its urea content and taking a plasma
sample during the PET. The dialysate-to-plasma creatinine
(D/P Cr) concentration ratio at four hours of dwell was
used to describe the peritoneal small solute transport rate.
The protein equivalent of nitrogen appearance (PNA) was
calculated using the Randerson15 formula and normalized
by the ideal body weight (nPNA). Residual renal function
was evaluated by collecting all urine over the same 24-hour
period as the dialysate collection. Residual glomerular
filtration rate (GFR; mL/minute) was calculated as the
mean of the renal urea and creatinine clearances.16
Statistical analysis
Statistical analyses were performed using Statistical
Package for Social Sciences (SPSS) version 13.0 for
WindowsH (SPSS Inc., Chicago, USA). Data are expressed
as the mean ¡ standard deviation (SD), unless otherwise
stated. The normality of data distributions was determined
using the Kolmogorov-Smirnov test. Comparisons between
groups were made using Student’s t-test and analysis of
variance (ANOVA) for normally distributed variables,
while the Mann-Whitney U test and Kruskall-Wallis
variance analysis were used for parametric variables with
non-normal distributions. The chi-square test was used to
analyze categorical data. A p-value of less than 0.05 was
considered statistically significant.
RESULTS
Thirty-five patients gave written informed consent to
participate in the study. Two patients did not complete the
vaccination program; one patient underwent transplanta-
tion, and one patient died. Therefore, 33 patients (13 women
and 20 men, mean age 49¡12 years) were included in the
final analysis. Only one patient was positive for antibodies
to hepatitis C virus (anti-HCV). The demographic, clinic,
and laboratory features of the patients are shown in Table 1.
After the fourth double dose of the vaccine, a response (anti-
HBs titer $10 IU/L) was observed in 28 (84.8%) of the
patients. No significant differences were observed for age,
time on dialysis, body mass index, urea, creatinine, hemoglo-
bin, serum albumin, nPNA, or hs-CRP between responders
and non-responders (Table 2). Similarly, weekly total Kt/V
(p=0.573), weekly peritoneal Kt/V (p=0.385) and residual
GFR (p=0.404) were not significantly different between
responders and non-responders. The response rate to immu-
nization was 86% among the 29 CAPD patients with a weekly
Kt/V of 1.7 or greater. This rate was not significantly different
as compared to the 75% response rate among the four CAPD
patients with lower values of weekly Kt/V (p=0.558).
Of the 28 patients responding to vaccination, seven patients
(25%) were weak responders, and 21 patients (75%) were
good responders. Time on dialysis, body mass index, urea,
creatinine, hemoglobin, serum albumin, nPNA, and hs-CRP
were not significantly different among non-responders, weak
Table 1 - Demographic, clinical, and laboratory
characteristics of 33 CAPD patients at study onset. Values
are expressed as the mean¡ SD, unless otherwise noted.
Variables n=33
Age 49¡12
Gender (F/M) 13/20
Cause of ESRD (%)
Hypertensive nephropathy 8 (24%)
Diabetic nephropathy 5 (15%)
Chronic glomerulonephritis 3 (9%)
Polycystic kidney disease 3 (9%)
Reflux nephropathy 2 (6%)
Amyloidosis 1 (3%)
Unknown 11 (33%)
Time on dialysis (months) 28¡23
Diabetes, n (%) 7(21)
Body mass index (kg/m2) 28.1¡4.9
Urea (mg/dL) 105¡40
Creatinine (mg/dL) 6.7¡3.5
Serum albumin (g/dL) 3.8¡0.5
Hemoglobin (g/dL) 11.3¡1.9
Hs-CRP (mg/dL) 1.06¡1.61
SD, standard deviation; ESRD, end stage renal disease; hs-CRP, high
sensitive C-reactive protein.
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responders and good responders (Table 3). A statistically
significant difference was observed across non-responders,
weak responders and good responders in age (54¡12 vs.
56¡9 vs. 45¡12 years, respectively; p=0.049) and rHuEpo
use (20 vs. 29 vs. 76%, respectively; p=0.016). There were no
statistically significant differences in weekly total Kt/V
(p=0.704), weekly peritoneal Kt/V (p=0.064) and the residual
glomerular filtration rate (p=0.355) across non-responders,
weak responders and good responders.
DISCUSSION
In the present study, we found an overall response rate
of 84.8%, which is comparable to the rates reported in
the literature for peritoneal dialysis patients (53% to
93.3%).2,10,11,17,18 Delivered clearance measured by weekly
peritoneal Kt/V, total clearance measured by weekly total
Kt/V, and residual GFR did not predict response to HBV
vaccination in the study’s patients treated with CAPD.
Regarding the effect of weekly total Kt/V on HBV
vaccination response, Dacko et al. examined the influence
of residual renal function and dialysis adequacy on HBV
vaccination response in 32 peritoneal dialysis (PD) patients.
Consistent with our findings, they found that the incident
residual renal function and the incident weekly Kt/V in
well-dialyzed peritoneal dialysis patients did not predict
responses to the hepatitis B vaccine.10 Similarly, Chow et al.
did not find a relationship between weekly total Kt/V and
immune response for 52 patients with ESRD on PD.12 More
recently, this same group of researchers evaluated the
factors associated with hepatitis B vaccine response in
87 PD patients and found that higher nPNA, but not weekly
Kt/V, was significantly associated with better vaccination
response.13 In contrast to our findings, however, Svac et al.
found a vaccination response rate of 78% for 40 PD patients
with a weekly Kt/V greater than 1.7 (n = 28) compared to a
response rate of just 8% in patients with a weekly Kt/V
below 1.7 (p = 0.0003).11 The limitations of their study,
however, included a lack of information on the vaccination
schedule and dose; in addition, the overall seroconversion
in their patients was only 53%. The proportion of patients
receiving inadequate dialysis in their study (30%) was larger
than in our study (12%), making comparisons difficult.
Based on our data and those of other reliable studies, total
clearance in peritoneal dialysis as measured via weekly total
Kt/V is not predictive of responses to HBV vaccination in
PD patients.
In ESRD patients, the inadequate antibody response
following HBV vaccination is multifactorial.1 In addition
Table 2 - Responses to four-dose HBV vaccination
schedule measured by anti-HBs titers and clinical,
laboratory, dialysis adequacy, and residual renal function
results in 33 peritoneal dialysis patients. Values are
expressed as the mean ¡ SD, unless otherwise noted.
Variables
Non-responders
,10 IU/L
Responders
$10 IU/L p-value
Subjects (n) 5 28 -
Age (years) 54¡12 48¡12 0.296
Time on dialysis (months) 18¡17 29¡23 0.379
Erythropoietin use, n (%) 1 (20) 18 (64) 0.065
Diabetes, n (%) 2 (40) 5 (18) 0.265
Body mass index (kg/m2) 29.1¡3.2 28.0¡5.2 0.641
Urea (mg/dL) 89¡28 108¡41 0.348
Creatinine (mg/dL) 6.3¡5.7 6.8¡3.1 0.291
Hemoglobin (g/dL) 10.6¡1.3 11.4¡1.9 0.498
Serum albumin (g/dL) 3.5¡0.7 3.8¡0.4 0.138
hs-CRP (mg/dL) 1.8¡1.4 0.9¡1.6 0.079
Weekly total Kt/V 2.9¡1.4 2.6¡1.1 0.573
Peritoneal Kt/V 1.5¡0.5 1.7¡0.5 0.385
RRF (mL/min) 4.7¡2.9 6.5¡4.0 0.404
Patients with RRF, n (%) 4 (80%) 23 (82%) 0.909
D/P creatinine 0.75¡0.18 0.73¡0.35 0.300
nPNA, g/kg/day 1.1¡0.5 1.2¡0.4 0.979
hs-CRP, high sensitive C-reactive protein; Kt/V, clearance of urea
normalized to total body water; RRF, residual renal function (patients
with RRF had a daily diuresis over 200 mL); D/P, dialysate/plasma; nPNA,
normalized protein equivalent of nitrogen appearance.
Table 3 - Responses to four-dose HBV vaccination schedule measured by anti-HBs titers and clinical, laboratory, dialysis
adequacy, and residual renal function values in 33 peritoneal dialysis patients. Values are expressed as the mean¡ SD,
unless otherwise noted. Statistically significant values are underlined.
Variables
Non-responders
,10 IU/L
Weak responders
10-100 IU/L
Good Responders
.100 IU/L p-value
Subjects (n) 5 7 21 -
Age (years) 54¡12 56¡9 45¡12 0.049
Time on dialysis (months) 18¡17 32¡22 29¡24 0.554
Erythropoietin use, n (%) 1 (20) 2 (29) 16 (76) 0.016
Diabetes, n (%) 2 (40) 0 (0) 5 (24) 0.220
Body mass index (kg/m2) 29.1¡3.2 27.9¡3.8 28.0¡5.6 0.897
Urea (mg/dL) 89¡28 96¡42 112¡41 0.437
Creatinine (mg/dL) 6.3¡5.7 6.9¡4.0 6.8¡2.8 0.551
Hemoglobin (g/dL) 10.6¡1.3 11.6¡1.8 11.4¡2.1 0.690
Serum albumin (g/dL) 3.5¡0.7 3.9¡0.5 3.8¡0.4 0.337
hs-CRP (mg/dL) 1.8¡1.4 0.8¡0.7 1.0¡1.9 0.212
Weekly total Kt/V 2.9¡1.4 2.8¡1.4 2.5¡0.9 0.704
Peritoneal Kt/V 1.5¡0.5 2.0¡0.7 1.6¡0.4 0.064
RRF (mL/min) 4.7¡2.9 8.3¡3.8 6.0¡4.0 0.355
Patients with RRF, n (%) 4 (80%) 5 (71%) 18 (86%) 0.693
D/P creatinine 0.75¡0.18 0.82¡0.61 0.70¡0.28 0.317
nPNA, g/kg/day 1.1¡0.5 1.4¡0.6 1.2¡0.4 0.798
hs-CRP, high sensitive C-reactive protein; Kt/V, clearance of urea normalized to total body water; RRF, residual renal function (patients with RRF had a
daily diuresis over 200 mL); D/P, dialysate/plasma; nPNA, normalized protein equivalent of nitrogen appearance.
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to age, many variables such as albumin levels,9 hepatitis C
infection,7 and erythropoietin deficiency1 may influence the
response of a patient to hepatitis B vaccine. In addition, cell-
mediated immunity factors such as impairment of monocyte
function, reduced T cell proliferation, and decreased
production of interleukin 2 are related to poor antibody
response.19,20 In the present study, we found that younger
PD patients had significantly better responses to HBV
vaccination. Similarly, a meta-analysis of 17 clinical trials
showed an increased response to hepatitis B virus vaccina-
tion among younger dialysis patients;21 these findings may
be due to age-associated changes in immune status. Our
study also showed that rHuEpo use in PD patients was
associated with better response to hepatitis B virus vaccina-
tion, a finding that suggests an immunomodulating effect of
rHuEpo.22 As found in other studies,7,10,23 the duration of
dialysis therapy as well as the levels of hemoglobin and
serum albumin failed to predict responses to the hepatitis B
vaccine in PD patients in this study. Fernandez et al.9 and
Kara et al.24, however, found that malnutrition in HD
patients, which is defined by low serum albumin levels,
negatively influenced responses to HBV vaccination. We
could not determine this association in our study because
we lacked a subgroup of malnourished patients. Only one
patient in our study had antibodies to hepatitis C virus,
making it difficult to determine the effects of HCV positivity
on hepatitis B vaccination responses.
The positive effects of dialysis adequacy, which are
characterized by single-pool Kt/V, on the response to HBV
in HD patients have been well documented.5 However,
given the results of both the present study and previous
research,10,12,13 this association may not be present in PD
patients. Clearance delivered continuously, as in PD, is more
efficient than the same amount of clearance delivered
intermittently, as in hemodialysis; thus, the Kt/V values are
not comparable.25 A limitation of our study is that the small
number of patients (n= 33) resulted in a small number of
patients in each vaccination response subgroup, which
precluded reliable statistical analysis of any differences. In
addition, the persistence of protective antibodies 12 months
after completion of the fourth dose was not measured.
CONCLUSIONS
We demonstrated that delivered clearance (measured by
weekly peritoneal Kt/V), total clearance (measured by
weekly total Kt/V), and residual GFR did not predict
responses to HBV vaccination in patients on CAPD. The
influence of dialysis adequacy on responses to hepatitis B
vaccination would be best studied in a larger group of PD
patients with wide variations in Kt/V and residual renal
function.
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